多发性骨髓瘤可靶向T细胞抗原的蛋白质组与蛋白质基因组鉴定
该研究对8例原发骨髓瘤样本和3个细胞系进行免疫肽组学分析,整合外显子与RNA测序鉴定肿瘤相关抗原和新生抗原。发现免疫球蛋白来源新生抗原在所有样本中存在且高度个体化,约30%细胞系来源肽段可诱导健康供者CD8+ T细胞应答,但患者来源新生抗原无免疫原性,提示免疫功能障碍。
要点
- 免疫球蛋白来源新生抗原在所有骨髓瘤样本中普遍存在且呈个体化。
- 约30%细胞系来源肽段可在异体HLA匹配健康供者PBMC中诱导CD8+ T细胞应答。
- 患者来源新生抗原在自体PBMC或TIL中均无免疫原性,提示严重免疫功能障碍。
核心结论
- 首次基于蛋白质基因组学鉴定多发性骨髓瘤新生抗原,拓展了免疫球蛋白来源新生抗原在B细胞淋巴瘤外的观察。
- 研究同时揭示了可靶向抗原和基于TCR免疫治疗面临的免疫功能障碍壁垒。
研究设计与样本
- 对8例原发多发性骨髓瘤样本和3个骨髓瘤细胞系进行基于质谱的免疫肽组学分析。
- 整合全外显子组和RNA测序,系统搜索肿瘤相关抗原和新生抗原。
主要发现
- 检测到癌症相关磷酸肽HLA配体及多种癌睾丸抗原来源HLA肽段,部分在肿瘤样本间共享。
- 蛋白质基因组分析显示主要为患者个体化的免疫球蛋白来源新生抗原,由V(D)J重排和体细胞超突变产生,存在于所有样本。
- 3例患者显示相关MHC II类肽配体在超突变区域聚集。
- 在原发样本和细胞系中均鉴定到非免疫球蛋白来源新生抗原。
- 约30%细胞系来源肽段在异体HLA匹配健康供者PBMC中诱导CD8+ T细胞应答,而患者来源新生抗原在自体PBMC或TIL中均无免疫原性。
临床怎么用
- 免疫球蛋白来源新生抗原可作为多发性骨髓瘤TCR或疫苗免疫治疗的潜在靶点。
- 患者来源新生抗原免疫原性缺失提示需克服免疫功能障碍以提升TCR免疫治疗疗效。
局限性
- 原发样本量较小(n=8),细胞系数量有限(n=3)。
- 患者来源新生抗原免疫原性评估仅基于自体PBMC和TIL,未涉及其他免疫激活策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) accounts for ∼12% of all hematologic malignancies and remains incurable despite therapeutic advances. Targeting tumor-associated antigens (TAAs) and tumor-specific neoantigens presented on HLA molecules by vaccination or T-cell receptor (TCR)-redirected T cells offers a promising novel immunotherapeutic strategy. However, knowledge of targetable tumor antigens, especially neoantigens, is limited. We applied a mass spectrometry-based immunopeptidomics approach on primary MM samples (n = 8) and MM cell lines (n = 3), integrating whole-exome and RNA sequencing to comprehensively characterize the MM immunopeptidome and systematically search for TAAs and neoantigens. Using our approach, we detected cancer-associated phosphopeptide HLA ligands as well as multiple cancer testis antigen-derived HLA peptides, some shared between tumor samples. Proteogenomic analysis revealed primarily personalized patient-specific immunoglobulin-derived neoantigens generated by variable diversity joining recombination and somatic hypermutation, which were present in all samples. Three patients showed clustering of related major histocompatibility complex class II peptide ligands within the hypermutated region. In addition, we identified non-immunoglobulin-derived neoantigens in both primary MM samples and cell lines. Approximately 30% of the cell line-derived peptides elicited CD8+ T-cell responses in allogeneic HLA-matched healthy donor peripheral blood mononuclear cells (PBMCs). In contrast, none of the patient-derived neoantigens were immunogenic in autologous PBMCs or tumor-infiltrating lymphocytes, reflecting severe immune dysfunction. This study provides, to our knowledge, the first proteogenomic-based identification of neoantigens in MM, extends the observation of presented immunoglobulin-derived neoantigens from B-cell lymphoma to MM, and highlights both actionable antigens and barriers to effective TCR-based immunotherapy.
引用
- Zuleger G, de Andrade Krätzig N, Giansanti P, et al. Proteomic and proteogenomic identification of targetable T-cell antigens in multiple myeloma. Blood Adv. 2026. PMID: 42486677. doi:10.1182/bloodadvances.2026019671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。